

Supplementary Table 5. Changes in lipid profiles during the study period in patients who did not receive any lipid-lowering agent at baseline or during the study period

Lipid profiles	Patients without lipid-lowering agent				P-value
	TAF 25 mg		TDF 300 mg		
	N	Median (IQR)	N	Median (IQR)	
Total cholesterol (mg/dL)					
Change* at month 6	725	3 (-9 to 19)	2,608	-5 (-23 to 12)	<0.001
Change* at month 12	628	4 (-13 to 21)	2,210	-6 (-25 to 12)	<0.001
Change* at month 18	559	3 (-14 to 22)	2,030	-8 (-27 to 12)	<0.001
Change* at month 24	462	4 (-14 to 24)	1,851	-9 (-27 to 12)	<0.001
Change* at month 30	379	5 (-11 to 25)	1,678	-8 (-27 to 12)	<0.001
Change* at month 36	315	8 (-9 to 24)	1,568	-9 (-28 to 12)	<0.001
Change* at month 42	259	5 (-11 to 20)	1,456	-8 (-28 to 13)	<0.001
Change* at month 48	169	6 (-12 to 22)	1,392	-7 (-27 to 13)	<0.001
HDL (mg/dL)					
Change* at month 6	321	0 (-5 to 3)	957	-2 (-9 to 1)	<0.001
Change* at month 12	281	-3 (-8 to 3)	788	-4 (-11 to 3)	0.018
Change* at month 18	243	-2 (-8 to 4)	706	-5 (-12 to 2)	<0.001
Change* at month 24	189	-2 (-10 to 3)	663	-5 (-13 to 1)	0.003
Change* at month 30	151	-2 (-8 to 4)	586	-5 (-13 to 1)	0.001
Change* at month 36	125	0 (-7 to 6)	564	-5 (-14 to 1)	<0.001
Change* at month 42	109	-1 (-7 to 4)	522	-6 (-14 to 1)	<0.001
Change* at month 48	57	0 (-8 to 4)	486	-6 (-14 to 1)	0.002
LDL (mg/dL)					
Change* at month 6	286	0 (-8 to 14)	487	0 (-12 to 10)	0.012
Change* at month 12	248	4 (-12 to 17)	353	-2 (-20 to 13)	0.004
Change* at month 18	217	3 (-10 to 16)	290	-4 (-19 to 10)	0.001
Change* at month 24	164	-1 (-14 to 16)	252	-6 (-22 to 9)	0.009
Change* at month 30	132	-1 (-14 to 10)	203	-6 (-22 to 11)	0.094
Change* at month 36	110	1 (-12 to 17)	197	-5 (-24 to 12)	0.022
Change* at month 42	89	-3 (-17 to 7)	162	-7 (-25 to 9)	0.206
Change* at month 48	42	-2 (-18 to 9)	138	-7 (-22 to 7)	0.284
Triglycerides (mg/dL)					
Change* at month 6	326	0 (-12 to 20)	973	-0 (-16 to 13)	0.002
Change* at month 12	285	3 (-15 to 27)	797	-4 (-24 to 15)	<0.001
Change* at month 18	248	6 (-11 to 22)	719	-5 (-23 to 12)	<0.001
Change* at month 24	193	5 (-14 to 28)	671	-4 (-21 to 18)	0.001
Change* at month 30	156	6 (-13 to 33)	596	-6 (-24 to 15)	<0.001
Change* at month 36	132	9 (-13 to 25)	575	-4 (-22 to 20)	0.001
Change* at month 42	113	12 (-8 to 36)	532	-4 (-22 to 16)	<0.001
Change* at month 48	61	4 (-14 to 28)	495	-2 (-21 to 21)	0.110

Supplementary Table 5. Continued

Lipid profiles	Patients without lipid-lowering agent				P-value
	TAF 25 mg		TDF 300 mg		
	N	Median (IQR)	N	Median (IQR)	
Total cholesterol / HDL ratio					
Change* at month 6	321	0.14 (−0.21 to 0.48)	957	0.10 (−0.31 to 0.51)	0.265
Change* at month 12	281	0.23 (−0.16 to 0.56)	787	0.15 (−0.34 to 0.54)	0.080
Change* at month 18	243	0.21 (−0.20 to 0.60)	706	0.19 (−0.29 to 0.59)	0.510
Change* at month 24	189	0.26 (−0.09 to 0.63)	663	0.17 (−0.29 to 0.62)	0.075
Change* at month 30	151	0.20 (−0.12 to 0.67)	586	0.19 (−0.27 to 0.66)	0.289
Change* at month 36	125	0.17 (−0.20 to 0.55)	564	0.22 (−0.27 to 0.66)	0.681
Change* at month 42	109	0.19 (−0.11 to 0.64)	521	0.24 (−0.24 to 0.68)	0.768
Change* at month 48	57	0.27 (−0.15 to 0.76)	486	0.25 (−0.23 to 0.74)	0.682

TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; IQR, interquartile range; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

*Indicates change from the baseline.